Rate of Spleen Length Progression is a Marker of Outcome in Patients with Primary Sclerosing Cholangitis
Standard
Rate of Spleen Length Progression is a Marker of Outcome in Patients with Primary Sclerosing Cholangitis. / Jung, Franziska; Cazzagon, Nora; Vettorazzi, Eik; Corpechot, Christophe; Chazouilleres, Olivier; Arrivé, Lionel; Lohse, Ansgar W; Schramm, Christoph; Ehlken, Hanno.
In: CLIN GASTROENTEROL H, Vol. 17, No. 12, 11.2019, p. 2613-2615.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Rate of Spleen Length Progression is a Marker of Outcome in Patients with Primary Sclerosing Cholangitis
AU - Jung, Franziska
AU - Cazzagon, Nora
AU - Vettorazzi, Eik
AU - Corpechot, Christophe
AU - Chazouilleres, Olivier
AU - Arrivé, Lionel
AU - Lohse, Ansgar W
AU - Schramm, Christoph
AU - Ehlken, Hanno
N1 - Original article, Research correspondence
PY - 2019/11
Y1 - 2019/11
N2 - Patients with primary sclerosing cholangitis (PSC) tend to develop progressive liver fibrosis and end-stage liver disease within 10-20 years. 1 The International PSC Study Group declared research on surrogate endpoints a high-priority task not least for ongoing clinical trials on novel treatment options. 2 The spleen in patients with PSC often enlarges even before cirrhosis develops. Transient elastography (TE) has been investigated as a dynamic and prognostic marker in PSC. 3,4 However, TE is not generally accessible, measures only a small part of the right liver, and is prone to errors in obese patients, and liver stiffness is related to postprandial status, liver inflammation, and biliary obstruction. 5 We have recently demonstrated that single-point spleen length (SL) measurement has a prognostic performance similar to liver stiffness measured by TE. 3,4,6 SL measurement is a fast, simple, and ubiquitously available method. However, absolute spleen size depends on body height and sex, 7 and single-point measurement of SL cannot be used to assess the effects of therapeutic interventions. To overcome these issues, we assessed the intra-individual development of spleen size over time (delta spleen length: dSL = SL 2 - SL 1) to evaluate its role as a novel surrogate marker, which accounts for the dynamic nature of PSC progression.
AB - Patients with primary sclerosing cholangitis (PSC) tend to develop progressive liver fibrosis and end-stage liver disease within 10-20 years. 1 The International PSC Study Group declared research on surrogate endpoints a high-priority task not least for ongoing clinical trials on novel treatment options. 2 The spleen in patients with PSC often enlarges even before cirrhosis develops. Transient elastography (TE) has been investigated as a dynamic and prognostic marker in PSC. 3,4 However, TE is not generally accessible, measures only a small part of the right liver, and is prone to errors in obese patients, and liver stiffness is related to postprandial status, liver inflammation, and biliary obstruction. 5 We have recently demonstrated that single-point spleen length (SL) measurement has a prognostic performance similar to liver stiffness measured by TE. 3,4,6 SL measurement is a fast, simple, and ubiquitously available method. However, absolute spleen size depends on body height and sex, 7 and single-point measurement of SL cannot be used to assess the effects of therapeutic interventions. To overcome these issues, we assessed the intra-individual development of spleen size over time (delta spleen length: dSL = SL 2 - SL 1) to evaluate its role as a novel surrogate marker, which accounts for the dynamic nature of PSC progression.
KW - Journal Article
U2 - 10.1016/j.cgh.2018.12.033
DO - 10.1016/j.cgh.2018.12.033
M3 - SCORING: Journal article
C2 - 30616025
VL - 17
SP - 2613
EP - 2615
JO - CLIN GASTROENTEROL H
JF - CLIN GASTROENTEROL H
SN - 1542-3565
IS - 12
ER -
